Media stories about Humanigen (NASDAQ:KBIO) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Humanigen earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.1421809694082 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Humanigen (KBIO) traded up 26.81% during mid-day trading on Friday, hitting $2.19. Humanigen has a 52-week low of $1.50 and a 52-week high of $4.75. The company has a 50 day moving average price of $1.84 and a 200-day moving average price of $2.45. The stock’s market cap is $32.80 million.
ILLEGAL ACTIVITY NOTICE: “Humanigen (KBIO) Getting Somewhat Positive News Coverage, Study Finds” was first published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/kalobios-pharmaceuticals-kbio-given-media-impact-rating-of-0-14-updated.html.
Humanigen, Inc, formerly KaloBios Pharmaceuticals, Inc, is a biopharmaceutical company. The Company focuses on developing medicines for patients with neglected and rare diseases, with an ancillary focus on pediatric conditions. The Company’s product candidate is benznidazole for the treatment of Chagas disease, a parasitic illness that can lead to long-term heart, intestinal and neurological problems.
Receive News & Ratings for Humanigen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen Inc and related companies with MarketBeat.com's FREE daily email newsletter.